GlassScriptPhysician profile
Ronald E Carroll
NPI 1790821122
$680.64
in general payments reported to CMS, 2019-2025
23 companies · $52.63 in 2025
The $52.63 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $71.52 · 2021: $122 · 2022: $142 · 2023: $62.49 · 2024: $44.16 · 2025: $52.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $159.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $76.74 | 2021 | |
| Novartis Pharmaceuticals Corporation | $76.15 | 2024-2025 | |
| Mylan Specialty L.P. | $54.20 | 2019-2023 | Yupelri |
| Novo Nordisk INC | $46.13 | 2019-2020 | |
| Lilly USA, LLC | $45.33 | 2019-2022 | |
| Amgen INC. | $33.56 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $31.69 | 2022 | |
| Sanofi-Aventis U.S. LLC | $31.61 | 2019-2022 | |
| Indivior INC. | $31.03 | 2019-2022 | |
| Allergan, INC. | $29.73 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.68 | 2021 | |
| Medtronic, INC. | $26.82 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.52 | 2023 | |
| Pfizer INC. | $20.64 | 2025 | |
| Gilead Sciences, INC. | $16.70 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $14.77 | 2022 | |
| Lucid Diagnostics INC. | $14.58 | 2022 | |
| Roche Diagnostics Corporation | $14.27 | 2019 | |
| Merck Sharp & Dohme LLC | $14.08 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.79 | 2019 | |
| Eisai INC. | $13.10 | 2020 | |
| Astellas Pharma US INC | $11.54 | 2019 | |
| Medtronic USA, INC. | $10.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Carroll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.